Treatment of Rheumatoid Arthritis with Golimumab Against the Disease Modifying Anti-Rheumatic Drugs and Infliximab Resistance
Kambham Venkateswarlu1*, Rajuprasad Yadav2
1Department of Pharmacoinformatics, 2Department of Biotechnology, National Institute of Pharmaceutical Education and Research (NIPER), Hajipur, Vaishali-844102, Bihar, India.
The safety and efficacy of Golimumab 50 mg (GLMB), for the treatment of rheumatoid arthritis (RA), was investigated by selecting the patients with resistance against the Infliximab and disease modified anti-rheumatic drugs (DMARDs). The patients with resistance to the Infliximab and DMARDs about 50 members were selected and divided into 2 groups as group A and group B. The investigational drug GLMB and placebo were administered to the group A and group B respectively. At predetermined intervals, the samples were collected and analyzed for the concentration of tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) present in the synovial fluid. After administration of test drug and placebo, the samples were collected at regular intervals of every 4 weeks upto 24 weeks and analyzed. The concentrations of TNF-α and IL-6, before and after administration of test drug, were compared and observed that the GLMB showed better efficacy than that of the placebo. It could be concluded from the results that the safety and efficacy of the investigational product has been achieved.
Key words: Cytokines, Efficacy, Golimumab, Multidrug resistance, Rheumatoid arthritis.